We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Amgen’s five-year legal challenge against Sanofi and Regeneron’s competitor for its cholesterol-lowering drug Repatha (evolocumab) is set to continue next month in a Delaware federal court.